

November 17, 2015



## OPKO Health to Present at the Jefferies Autumn 2015 Global Healthcare Conference

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Autumn 2015 Healthcare Conference on Wednesday, November 18, 2015, at 2:00 GMT in London, England.

The presentation will be webcast on the OPKO Investor Relations page of the corporate website at [www.opko.com](http://www.opko.com). To access the live webcast please log on to the OPKO site approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

### About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151117006650/en/>

OPKO Health, Inc.  
Tara Mackay, 305-575-4100  
Investor Relations  
or

### Media:

Rooney & Associates  
Terry Rooney, 212-223-0689  
[trooney@rooneyco.com](mailto:trooney@rooneyco.com)  
or  
Marion Janic, 212-223-4017  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

or

**Investors:**

LHA

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss, 310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: OPKO Health, Inc.